In an industry that grapples with high failure rates, it is important to recognize the successes and the hard work put in by biopharma companies as well as firms supporting those efforts. The Citeline Awards are our way to honor the research and development activity that drives the industry and meets the urgent needs of patients. The Awards are your chance to bring recognition and raise awareness of your innovative R&D work.
Publisher’s Spotlight: The Citeline Awards Are Open For Entries!
Submit your drug development programs for recognition at the 2025 Citeline Awards. The deadline has been extended to 28 February.
More from Pink Sheet
• By
A Republican think tank suggested variations of the Most Favored Nation and international reference policies in Medicare and Medicaid, as well as tariffs and other trade levers to rebalance drug pricing disparities between US countries and abroad.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Results from a single-arm study cannot support representations on overall survival, progression-free survival and disease control rate for the cancer drug, the Office of Prescription Drug Promotion said in another “untitled” letter implicating the agency’s CFL guidance.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.